George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- July31 2004
- Volume 11
- Issue 14
Online Help
Author(s)Ellen Rabinowitz
Advertisement
The following Web sites can help physicians better evaluate stocks:
- Yahoo! Finance (finance.yahoo. com): In addition to providing company news, Yahoo! is a good source for historical prices. It provides the price for any stock on any date.
MultexInvestor (www.multexin vestor.com): This Web site uses all of the tools mentioned here to show how a particular stock stands in relation to its industry and sector. Enter a ticker symbol and click on "ratios and comparisons" to evaluate a stock.
- Morningstar (www.morningstar. com): Morningstar is a good source for information on mutual fund ownership.
CBS MarketWatch (cbs.market watch.com): Here you'll find the 50- day moving average chart.
- Quicken (www.quicken.com): Quicken has its own stock evaluation system that charts the performance of companies vs industries over the past 10 years.
Articles in this issue
about 18 years ago
Blend the Money in Your Blended Familyabout 18 years ago
Build College Savings Earlyabout 18 years ago
Think Positive and Success Will Followabout 18 years ago
Popping the Questionabout 18 years ago
More Retirement Plansabout 18 years ago
Canceling Cheap Ticketsabout 18 years ago
Your Average Deductionabout 18 years ago
Avoiding Probate Fightsabout 18 years ago
Ask Your Brokerabout 18 years ago
Scandal Bypasses CongressAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
2
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5